An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

Summary

The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.

Timeline

Start

2025-09-30

Primary completion

2029-05-03

Completion

2029-05-17

Drugs

Indications